Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Urology. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

story of the week

Journal Scan / Research · April 28, 2022

High-Dose Radiotherapy and Risk-Adapted Androgen Deprivation in Localised Prostate Cancer

The Lancet Oncology


Additional Info

The Lancet Oncology
High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial
Lancet Oncol 2022 Apr 12;[EPub Ahead of Print], A Zapatero, A Guerrero, X Maldonado, A Álvarez, CG San-Segundo, MÁC Rodríguez, JM Solé, AP Olivé, F Casas, A Boladeras, CM de Vidales, MLV de la Torre, S Vara, JL Sanz, FA Calvo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer Center of Excellence

Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.

Further Reading